Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Improving transparency and traceability within the supply chain’s first mile

How manufacturers can implement processes to help improve this critical part of the supply chain

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

Phenylketonuria affects one in every 13,500 to 19,000 newborns in the US

- PMLiVE

Motivating low-performance teams

Why some teams act in the same way as organisms that are metabolically impaired

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

Celebrating the Cannes Lions International Festival of Creativity

Cannes’ most forward-looking conversations weren’t about pharma – but pharma should have been listening

New team members

Cuttsy+Cuttsy welcomes new team members

Cuttsy+Cuttsy is excited to announce the addition of three talented professionals to the team: Flo, an enthusiastic Account Executive; Vicki, a creative Graphic Designer; and Jo, a detail-driven Artworker

Cuttsy + Cuttsy

Unlocking the future of Learning

By Potter Li and Aaron Fletcher

Amiculum

- PMLiVE

Medical Misinformation and Sensationalism in the Age of Social Media

In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content. These sources of misinformation often overshadow evidence-based content, creating confusion for both healthcare...

Medscape Education

- PMLiVE

Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

The rare bleeding disorder affects approximately 800,000 people globally

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links